|John J. Rydzewski|
Executive Chairman of the Board of Directors and Co-Founder
John has been Executive Chairman since October 2011. He has significant life sciences industry experience as an institutional investor, investment banker and corporate director. Before joining Enumeral, John was managing director of Christofferson, Robb & Co., an investment firm where he monetized life-sciences intellectual property covering large and small molecule therapeutics from July 2006 to September 2011. His banking career included partnership responsibilities at Benedetto, Gartland & Co., an investment bank serving corporate and institutional clients, and officer positions in the merchant banking and healthcare specialty finance units of Kidder, Peabody & Co. and Dean Witter Reynolds. Prior to banking, John was a manager in the Bankruptcy Services Group of Price Waterhouse & Co., and he held positions in industry. He continues to serve as a director of several healthcare companies, including Vision-Sciences, Inc., and he is Co-Chairman of the Board of Advisors of the RAND Corporation’s health policy research unit. John received an M.B.A. and a B.S. in economics with honors from The Wharton School of the University of Pennsylvania.
|Barry Buckland, Ph.D.|
Chairman, Scientific Adivsory Board, Enumeral
Chief Executive Officer, BiologicB
Dr. Buckland has been a member of our Board of Directors since 2009. His career in the pharmaceutical industry includes leadership of Merck’s world class Bioprocess Research and Development Group which saw the market launch of major biological products, including Gardasil®, Rotateq®, and Zostavax®. Dr. Buckland has been the Chief Executive Officer of BiologicB, a consulting firm working with biotechnology and vaccine products, since 2009. He is the recipient of numerous awards, among them the Donald Medal, UK Institute of Chemical Engineering in 2002, Prix Galien award as a member of the team that received the Vaccine Award for Gardasil in 2007, the Marvin Johnson award by ACS for lifetime contribution to Biotechnology in 2008, and the PhRMA Discoverer of the Year for development of the Merck HPV vaccine (along with Eliav Barr and Kathrin Jansen) in 2009. Dr. Buckland has chaired multiple International Conferences related to bioprocess research and development and vaccine technology and is an author on over 70 papers. He has been a Visiting Professor at University College London since 1995. Dr. Buckland earned his Ph.D. in biochemical engineering at University College London.
|Robert J. Easton|
Co-chairman, Bionest Partners, Inc.
Mr. Easton has been a member of our Board of Directors since 2015. He is a recognized leader in the life sciences and healthcare industries, having led strategy development and supervised opportunity assessments for hundreds of clients across the globe, including large and specialty pharmaceutical companies, early-stage and publicly traded biopharmaceutical companies, and diagnostics businesses. Mr. Easton currently serves as Co-chairman of Bionest Partners, Inc., a consulting firm he co-founded that specializes in strategic planning for pharmaceutical, medical device and diagnostic companies. Prior to co-founding Bionest Partners, Mr. Easton built and led two consulting firms, Easton Associates and The Wilkerson Group, which provided advisory services in the healthcare, pharmaceuticals and medical products industries. Previously, Mr. Easton spent 12 years in various management roles at Union Carbide and Union Carbide Europe, including in marketing and engineering in the clinical diagnostics business unit. Mr. Easton has served since 2002 on the Board of Directors of Cepheid, a molecular diagnostics company, where he also serves on the Nominating and Governance Committee. He currently serves as chairman of the New York Biotechnology Association, and also serves on the Board of Advisors of the Global Cardiovascular Innovation Center at the Cleveland Clinic. Mr. Easton holds B.S. and B.A. degrees in chemical engineering from Rice University, and an M.B.A. from Harvard University. Mr. Easton serves as Chairman of our Audit Committee.
|Allan P. Rothstein|
Principal, Hedge Capital Partners
Mr. Rothstein has been a member of our Board of Directors since 2013. He has over 30 years of experience in the financial services industry and is currently Principal of Hedge Capital Partners, an investment vehicle for venture capital, portfolio management and asset management. From 2011 to 2014, he was a principal of Healthcare Recovery Services, which serves financial aspects and enhances revenue cycles of hospitals and other healthcare service enterprises. From 2010 to 2011, Mr. Rothstein was head of trading at Centurion Partners. He is also the owner of Shizoom, a business funding company. Prior to Hedge Capital Partners, he was Senior Vice President and co-head of NASDAQ trading at Fahnestock & Company (now Oppenheimer & Company). Mr. Rothstein started his career at Shearson Loeb Rhoades, handling arbitrage lines for domestic and international customers. He served as a member of the National Nanotechnology Business Alliance and the New York Nanotechnology Business Alliance advisory boards and the Dean’s Council of the Graduate School of SUNY Stonybrook. Mr. Rothstein graduated as a Benjamin Franklin Scholar from the University of Pennsylvania.
|Paul J. Sekhri|
President, Chief Executive Officer and Director, Lycera
Mr. Sekhri is an accomplished industry executive, with more than 25 years of experience in life sciences strategy, corporate development and corporate finance, having served in senior leadership positions at several pharmaceutical companies. He is currently President and Chief Executive Officer of Lycera, and he also serves on its board of directors. Prior to joining Lycera, Mr. Sekhri was Senior Vice President, Integrated Care at Sanofi, and before that, he served as Group Executive Vice President, Global Business Development and Chief Strategy Officer at Teva Pharmaceutical Industries. Prior to this, Mr. Sekhri was Operating Partner and Head, Biotech Operations Group at TPG Biotech, where he was responsible for a portfolio of more than 50 life science firms. Previously, Mr. Sekhri was founder, President and Chief Executive Officer of Cerimon Pharmaceuticals, and before Cerimon, he was President and Chief Business Officer of Ariad Pharmaceuticals. He also held senior positions at Novartis, including Senior Vice President and Head, Global Search and Evaluation and M&A. Mr. Sekhri is also a director of Veeva Systems and has served as a director on numerous private and public company boards, including KAI Pharmaceuticals, Intercept Pharmaceuticals, Macrogenics, PatientSafe Solutions and Tandem Diabetes, and as a board advisor to IMS Health. He serves on the Board of Trustees for the non-profit Cancer Research Institute and on the Industry Advisory Boards of the Michael J. Fox Foundation, the TB Alliance and the Tectonic Theatre Project. Mr. Sekhri received a B.S. from the University of Maryland and completed postgraduate studies in clinical anatomy and neuroscience at the University of Maryland, School of Medicine.
|Arthur H. Tinkelenberg, Ph.D.|
President, Chief Executive Officer, Director and Co-Founder
Arthur has been President, Chief Executive Officer and a director since 2010. He has broad experience in the business and finance of healthcare enterprises and basic life sciences research. Prior to joining Enumeral, he was a partner in Ascent Biomedical Ventures, a life sciences venture capital firm focused on early-stage biomedical technologies, where he was responsible for originating and managing numerous biotechnology and medical device company investments from 2003 through 2009. Prior to venture capital, he served in the healthcare corporate finance and mergers and acquisitions group of Robertson Stephens. Before industry, he conducted research in lipid metabolism, genomics and cell biology as a Research Scientist at Columbia University from 1996 through 2000. He is a published author and inventor on a number of patents. He received his Ph.D. in molecular genetics from the Rockefeller University and his B.A. in biology from Grinnell College.
|Robert L. Van Nostrand|
Former Chief Financial Officer, OSI Pharmaceuticals
Mr. Van Nostrand has been a member of our Board of Directors since 2014. He is a seasoned biotechnology executive with an extensive background in finance, operations and accounting in public biotechnology companies in all stages of development. Most recently, Mr. Van Nostrand held senior executive positions with AGI Dermatics and Aureon BioSciences. For 21 years, he served in executive leadership positions at OSI Pharmaceuticals, including Chief Compliance Officer, Chief Financial Officer and Chief Accounting Officer. During his tenure with OSI Pharmaceuticals, he had financial responsibility for all of its significant operations and was instrumental in development of strategy, budgeting and forecasting, negotiation and closing of several major corporate collaborations, and SEC reporting. During his tenure, Mr. Van Nostrand led the OSI financial team in raising over $1.4 billion in equity and debt during a time of high growth as OSI transitioned from an early-stage biotechnology company to a multi-billion dollar, commercial-stage organization. Prior to joining OSI, he was a manager at Touche Ross & Co (currently Deloitte). Mr. Van Nostrand currently serves on the boards of several other publicly traded biotechnology companies, including Metabolix, where he is chairman, Achillion Pharmaceuticals and Intra-Cellular Therapies. Mr. Van Nostrand also serves as the chairman of the audit committee for each of these companies. In addition, Mr. Van Nostrand serves on the board of directors of the Biomedical Research Alliance of New York. He is the former Chairman, and currently serves on the board, of NYBio (formerly the New York Biotechnology Association) and also serves on the Foundation Board of Farmingdale University. Mr. Van Nostrand received a B.S. in accounting from Long Island University and studied management at The Wharton School of the University of Pennsylvania. He is a Certified Public Accountant.